Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.38 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627396 | 0.89 | MGLL (0.68) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL2919855 | 0.87 | MGLL (0.50) | MGLLKCNH2CFTRCCKARPIK3CD | |
| SCHEMBL5271456 | 0.86 | MGLL (0.45) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL5270160 | 0.86 | KCNH2 (0.46) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL5269466 | 0.85 | MGLL (0.49) | MGLLCCKAR | |
| SCHEMBL5266892 | 0.85 | MGLL (0.41) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL2911608 | 0.85 | MGLL (0.46) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL2919465 | 0.85 | MGLL (0.46) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL2914801 | 0.85 | MGLL (0.48) | MGLLKCNH2CFTRCCKARBRD4 | |
| SCHEMBL2921251 | 0.84 | MGLL (0.45) | MGLLKCNH2CFTRCCKARPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | MGLL 4176/4885KCNH2 2311/4885CFTR 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.